
Microbot Medical (MBOT) Stock Forecast & Price Target
Microbot Medical (MBOT) Analyst Ratings
Bulls say
Microbot Medical Inc. has notably strengthened its financial position through successful equity financings, resulting in improved financing income of $284K for the recent quarter and $611K year-to-date, an increase from the previous year's $85K and $144K, respectively. The company is preparing for a significant product launch of its LIBERTY Endovascular Robotic Surgical System in the U.S. and Europe, with positive feedback from providers indicating strong market potential and a competitive edge in the minimally invasive surgery segment. Additionally, enhancements to their operational capabilities, including an expanded commercial team and a partnership with a third-party logistics provider, position Microbot Medical for accelerated growth in the coming years, reinforcing a favorable outlook for the company's stock.
Bears say
Microbot Medical Inc faces significant risks that contribute to a negative outlook on its stock, including delays in commercialization and challenges in expanding its device applications into neuro and cardio surgeries. Additionally, the company is grappling with reimbursement headwinds and a lack of profitability in the near term, which may hinder its financial performance and market adoption of its LIBERTY platform. The absence of solid data from randomized controlled trials and potential delays in securing necessary international regulatory approvals further exacerbate the uncertainties surrounding its future growth prospects.
This aggregate rating is based on analysts' research of Microbot Medical and is not a guaranteed prediction by Public.com or investment advice.
Microbot Medical (MBOT) Analyst Forecast & Price Prediction
Start investing in Microbot Medical (MBOT)
Order type
Buy in
Order amount
Est. shares
0 shares